ImmunityBio, Inc. 8-K

What Happened
ImmunityBio, Inc. announced its financial results and provided a business update for the three months ended March 31, 2026 via a press release dated May 7, 2026. The company furnished that press release on Form 8-K (filed May 7, 2026) under Item 2.02 (Results of Operations and Financial Condition); the full press release is included as Exhibit 99.1 to the filing.

Key Details

• Date of filing: May 7, 2026 (Form 8-K).
• Period covered: financial results and financial position for the three months ended March 31, 2026.
• Exhibit included: Press release dated May 7, 2026 (Exhibit 99.1) and Inline XBRL cover page (Exhibit 104).
• Item reported: 2.02 (Results of Operations and Financial Condition); exhibits furnished under Item 9.01.

Why It Matters
This 8-K provides investors with ImmunityBio’s latest quarterly results and a management business update — information that can affect near-term valuation, investor sentiment, and trading. Retail investors should read the furnished press release (Exhibit 99.1) and related SEC filings to see reported revenue, expenses, cash position, and any operational or clinical updates that could influence the company’s outlook.